|
|
|
|
| LEADER |
00000cam a2200000Ii 4500 |
| 001 |
SCIDIR_on1308508772 |
| 003 |
OCoLC |
| 005 |
20231120010638.0 |
| 006 |
m o d |
| 007 |
cr cnu---unuuu |
| 008 |
220401s2022 mau o 000 0 eng d |
| 040 |
|
|
|a OPELS
|b eng
|e rda
|e pn
|c OPELS
|d OCLCO
|d OCLCF
|d SFB
|d OCLCQ
|d OCLCO
|
| 020 |
|
|
|z 9780323988476
|q (print)
|
| 035 |
|
|
|a (OCoLC)1308508772
|
| 050 |
|
4 |
|a RB40
|
| 082 |
0 |
4 |
|a 616.0756
|2 23
|
| 245 |
0 |
0 |
|a Advances in clinical chemistry.
|n Volume 107 /
|c Edited by Gregory S. Makowski.
|
| 264 |
|
1 |
|a [Place of publication not identified] :
|b Academic Press,
|c 2022.
|
| 300 |
|
|
|a 1 online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
0 |
|
|a Advances in clinical chemistry ;
|v volume 107
|
| 588 |
0 |
|
|a Online resource; title from PDF title page (ScienceDirect, viewed April 1, 2022).
|
| 505 |
0 |
|
|a Intro -- Advances in Clinical Chemistry -- Copyright -- Contents -- Contributors -- Preface -- Chapter One: Advances in quantum dots as diagnostic tools -- 1. Introduction -- 2. Quantum dots: Synthesis, functionalization and characterization -- 2.1. Synthetic procedures -- 2.1.1. Top-down processing methods -- 2.1.2. Bottom-up processing methods -- 2.2. Solubilization and functionalization -- 2.2.1. Aqueous stabilization of QDs -- 2.2.2. Bioconjugation of QDs -- 2.3. Analytical tools for QD characterization -- 2.3.1. Morphological information -- 2.3.2. Crystallographic information -- 2.3.3. Chemical composition -- 2.3.4. Surface characterization -- 2.3.5. Bioconjugation efficiency -- 3. Quantum dots for point-of-care (POC) diagnosis -- 3.1. POC devices: Role of QDs -- 3.2. Optical and electrochemical methods for QD biosensing tag detection -- 3.3. POC systems based on QD barcode technology -- 3.4. Paper-based POC diagnostic devices using QDs -- 3.4.1. Lateral-flow principles: Optical detection -- 3.4.2. Smartphone integration -- 3.4.3. Paper-based devices with electrochemical detection -- 3.4.4. Emerging nanopaper platforms -- 4. Ultrasensitive biomarker detection based on quantum dots -- 5. Bioconjugated quantum dots for molecular imaging -- 5.1. Bioconjugated QDs for fluorescence molecular imaging -- 5.2. Near-infrared optical imaging -- 5.3. Multimodal imaging -- 6. Summary and future perspectives -- Acknowledgments -- References -- Chapter Two: Host polymorphisms and COVID-19 infection -- 1. Introduction -- 2. Genetic polymorphisms affecting the angiotensin-converting enzyme 2 expression (Table 1) -- 2.1. Angiotensin-converting enzyme 2 -- 2.2. Transmembrane serine protease 2 -- 2.3. Androgen receptor -- 2.4. A disintegrin and metalloproteinase 17 -- 2.5. Angiotensin-converting enzyme 1.
|
| 505 |
8 |
|
|a 3. Genetic polymorphisms affecting the immune response against COVID-19 (Table 2) -- C-C chemokine receptor 5 -- 3.2. Complement C3 -- 3.3. Interferon-induced transmembrane protein 3 -- 3.4. Tumor necrosis factor-alpha -- 3.5. Toll-like receptor 7 -- 3.6. Apolipoprotein E -- 3.7. Vitamin D binding protein -- 3.8. Dipeptidyl peptidase -- 3.9. Glutathione S-transferase theta 1 -- 4. Associated genetic polymorphisms (Table 3) -- 4.1. ABO blood group -- 4.2. Human leukocyte antigen system -- 4.3. Haplogroup R -- 4.4. Neanderthal DNA -- 5. Conclusion -- References -- Chapter Three: Clinical metabolomics for inborn errors of metabolism -- 1. Introduction -- 2. Overview of metabolomics -- 3. Overview of inborn error of metabolism laboratory diagnosis -- 4. Analytical methodology -- 4.1. Sample extraction -- 4.2. Analytical instrumentation and methods -- 4.3. The importance of library-based bioinformatics methodology -- 4.4. Authentic standard library -- 4.5. Quality control and data alignment -- 4.6. Data curation -- 5. Computations for reference population comparisons -- 6. Bridging to reference populations and other analytical considerations -- 6.1. Bridging to the reference population -- 6.2. Process quality control -- 6.3. Compound performance criteria -- 6.3.1. Analytical performance -- 6.3.1.1. Precision studies -- 6.3.1.2. Platform correlation studies -- 6.3.1.3. Median ratio studies -- 6.3.1.4. Compound stability studies -- 6.3.2. Biological relevance -- 6.4. Preanalytical sample quality assessment -- 6.5. Reporting and limitations -- 7. Clinical utility of metabolomics for the identification of IEMs -- 7.1. Application in rare disease profiling -- 7.2. Rare disease characterization and therapeutic monitoring -- 7.3. Adjunct to exome sequencing -- 8. Future applications and challenges -- 9. Conclusions -- References.
|
| 505 |
8 |
|
|a Chapter Four: Amino acids in inflammatory bowel diseases: Modern diagnostic tools and methodologies -- 1. Introduction -- 2. Inflammatory bowel diseases -- 2.1. Risk factors of IBD -- 2.2. Therapy of inflammatory bowel disease -- 3. Biomarkers of inflammatory bowel disease -- 4. Amino acids as biomarkers and their role in inflammatory bowel disease -- 5. Analytical strategies for analysis of amino acids in biological samples -- 5.1. Sample preparation -- 5.1.1. Solid-phase extraction and solid-phase microextraction -- 5.1.2. Liquid-liquid extraction -- 5.1.3. Protein precipitation -- 5.1.4. Electrophoretic preconcentration -- 5.1.5. Derivatization -- 5.2. Chromatographic techniques -- 5.2.1. Detection in liquid chromatography -- 5.2.2. Practical applications of chromatographic methods in bioanalysis of amino acids -- 5.3. Capillary electrophoresis -- 5.3.1. Detection in capillary electrophoresis -- 5.3.2. Practical applications of electromigration methods in bioanalysis of amino acids -- 6. Current studies of amino acids in IBD -- 7. Conclusion -- Acknowledgments -- Conflict of interest -- References -- Chapter Five: Advances in sports genomics -- 1. Introduction -- 2. Genome-wide association (GWAS) and whole genome sequencing (WGS) studies in sport -- 2.1. Genome-wide association studies -- 2.2. Whole genome sequencing study -- 3. Gene variants for endurance athlete status -- 4. Gene variants for power athlete status -- 5. Gene variants for strength athlete status -- 6. Gene variants for soft tissue injuries -- 7. Conclusion -- References -- Chapter Six: Biomarkers in muscle invasive bladder cancer -- 1. Introduction -- 2. Current treatment of MIBC -- 2.1. Cystectomy versus radiotherapy -- 2.2. Radiosensitizing agents -- 2.3. Neoadjuvant and adjuvant therapy -- 3. The unmet need for robust biomarkers in MIBC -- 4. Urinary biomarkers.
|
| 505 |
8 |
|
|a 5. Gene expression signatures predicting lymph node metastasis -- 6. Biomarkers of anti-tumor immunity -- 6.1. PD-1/PD-L1 -- 6.2. Lymphocytopenia -- 7. Hypoxia biomarkers -- 8. Biomarkers of DNA damage repair -- 8.1. MRE11 -- 8.2. ERCC1 and XRCC1 -- 8.3. ATM/RB1/FANCC -- 8.4. AIMP3 -- 9. Clinical trials of poly ADP ribose polymerase (PARP) inhibitors -- 10. Other molecular biomarkers -- 10.1. p53 -- 10.2. EGFR family -- 11. Molecular taxonomy -- 12. The fibroblast growth factor receptor (FGFR) pathway -- 13. Liquid biopsy -- 14. Micro-RNA -- 15. Conclusion -- Funding -- Acknowledgments -- References -- Index.
|
| 650 |
|
0 |
|a Clinical chemistry.
|
| 650 |
|
2 |
|a Chemistry, Clinical
|0 (DNLM)D002624
|
| 650 |
|
6 |
|a Chimie clinique.
|0 (CaQQLa)201-0016714
|
| 650 |
|
7 |
|a Clinical chemistry
|2 fast
|0 (OCoLC)fst00864330
|
| 700 |
1 |
|
|a Makowski, Gregory S.
|q (Gregory Stephen),
|e editor.
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/bookseries/00652423/107
|z Texto completo
|
